Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms- |
Target |
Action agonists, inhibitors |
Mechanism CD28 agonists(T-cell-specific surface glycoprotein CD28 agonists), CD38 inhibitors(Lymphocyte differentiation antigen CD38 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Multiple Myeloma | Preclinical | China | 29 Apr 2025 |